{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"142"}]}],"title":"Baseline Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"104"}]}],"title":"Baseline Negative: -'ve Postbaseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"27"}]}],"title":"Baseline Negative: Transiently +'ve Postbaseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}]}],"title":"Baseline Negative: Persistently +'ve Postbaseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"}]}],"title":"Baseline Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}],"title":"Baseline Positive: -'ve Postbaseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}],"title":"Baseline Positive: Transiently +'ve Postbaseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}]}],"title":"Baseline Positive: Persistently +'ve Postbaseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"groups":[{"description":"brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"},{"description":"placebo every 3 weeks by IV infusion","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"ATA-evaluable patients (patients with a baseline and at least 1 postbaseline sample)","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Incidence of Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin","type":"SECONDARY","unitOfMeasure":"participants"}